Cerebrospinal fluid (CSF)-based molecular tests can reliably distinguish multiple sclerosis (MS) from other neurological ...

Validation Data on More Than 100 Patients published in Journal of Molecular Diagnostics CHICAGO, April 25, 2025 /PRNewswire/ -- Belay Diagnostics, a CLIA/CAP accredited laboratory focused on the ...

Summit (TM) 2.0 is a CSF-based liquid biopsy assay designed to enable comprehensive genomic profiling for characterization of CNS tumors. CNS malignancies present unique diagnostic challenges, as ...

Researchers with the Johns Hopkins Kimmel Cancer Center, the Johns Hopkins University School of Medicine and four other institutions have developed a molecular test to identify the presence of brain ...

Despite extensive use of biomarkers in research studies, most Alzheimer’s disease diagnoses in the United States are determined by clinical examination. That may be about to change. The Food and Drug ...

A novel, multi-analyte test developed by researchers at the Johns Hopkins Kimmel Cancer Center, its Ludwig Center and the Johns Hopkins Department of Neurosurgery can accurately identify brain cancers ...

GENT, Belgium & MALVERN, Pa. & TOKYO, January 28, 2026--(BUSINESS WIRE)--H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today announced the availability of the Lumipulse G pTau 217 ...

Add Yahoo as a preferred source to see more of our stories on Google. A new brain cancer test using spinal fluid detects tumors with 100% accuracy, offering safer diagnosis and fewer risky biopsies.

As the world’s population ages, health experts are bracing for higher rates of age-related diseases, including Alzheimer’s. Finding new ways to diagnose the condition is more of a priority than ever, ...